Brief: Bioarctic And Eisai Says Sign Research Evaluation Agreement Regarding BAN2802
20/04/2024 08:42
April 20 (Reuters) - BioArctic AB BIOAb.ST :
* BIOARCTIC AND EISAI SIGN RESEARCH EVALUATION AGREEMENT
REGARDING
BAN2802
* BIOARCTIC - EISAI WILL EVALUATE DATA GENERATED AND DECIDE
IF
THEY CHOSE TO EXERCISE AN OPTION TO LICENSE BAN2802 FOR
TREATMENT OF ALZHEIMER'S DISEASE
Source text for Eikon: ID:nWkr4SprpZ
Further company coverage: BIOAb.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million